Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires $44,600.00 in Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the stock in a transaction on Tuesday, February 25th. The stock was acquired at an average cost of $4.46 per share, for a total transaction of $44,600.00. Following the acquisition, the chief executive officer now owns 2,331,730 shares in the company, valued at approximately $10,399,515.80. This represents a 0.43 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Vanda Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ VNDA opened at $4.70 on Friday. The stock has a market cap of $274.09 million, a price-to-earnings ratio of -14.69 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a 1-year low of $3.71 and a 1-year high of $6.75. The stock’s 50-day moving average is $4.59 and its 200 day moving average is $4.80.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The business had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. On average, analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on VNDA shares. HC Wainwright raised their price target on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. StockNews.com started coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a “hold” rating on the stock.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of VNDA. SG Americas Securities LLC grew its position in Vanda Pharmaceuticals by 88.5% during the 3rd quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 9,580 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 4,374 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter worth approximately $143,000. Empowered Funds LLC grew its position in shares of Vanda Pharmaceuticals by 5.3% in the 3rd quarter. Empowered Funds LLC now owns 228,287 shares of the biopharmaceutical company’s stock worth $1,071,000 after buying an additional 11,524 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Vanda Pharmaceuticals by 7.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 780,933 shares of the biopharmaceutical company’s stock worth $3,663,000 after buying an additional 55,567 shares during the last quarter. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.